Dr. Sadiq Lafta Altamimi, MD

Dr. Altamimi practices at The Neurology Group Inc in Pomona, California.

Dr. Altamimi's NPI, 1639381619, was assigned on May 4, 2007. Dr. Altamimi graduated from St. George's University School of Medicine in 2004. Dr. Altamimi holds California license A128441.

Dr. Altamimi's primary practice is The Neurology Group Inc, at 2895 N Towne Ave, Pomona, CA 91767 in Los Angeles County. The practice phone is (909) 267-7495.

Dr. Altamimi's primary practice is The Neurology Group Inc in Pomona, California. Dr. Altamimi is also affiliated with Pomona Valley Hospital Medical Center. The medical group on file is The Neurology Group. Dmand AI also links Dr. Altamimi to 1 more hospital, 2 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Altamimi practices, 5 sites in all. Vendor and product names are available with a free account.

Clinical neurophysiology is Dr. Altamimi's primary specialty in the NPI Registry, under taxonomy code 2084N0600X. Dr. Altamimi is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Altamimi's licenses on file in 6 states: California, Michigan, Indiana, Nevada, Illinois and Pennsylvania.

Dmand AI lists acute mini-stroke (TIA), carpal tunnel syndrome, cerebrovascular disease, epilepsy, essential tremor, fibromyalgia and chronic pain, hereditary polyneuropathy and lower back pain among the conditions Dr. Altamimi treats.

CMS data shows 6,219 Medicare services from Dr. Altamimi across 16 procedure codes in 2024, for 703 Medicare patients. Medicare paid $370,272 for them. Every service was in an office.

CMS counts 703 Medicare patients who saw Dr. Altamimi in 2024. The largest group is 65 to 74, with 259 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 58% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Altamimi's median patient age at 59, with 61% women.

In 2024, Dr. Altamimi wrote 7,568 Medicare Part D claims for 1,053 patients. 81% of them were for generic drugs. CMS names the drug for 7,302 of them, across 99 drugs with 11 or more claims each, at $11,171,444 in total drug cost. In 2023, CMS named 6,208 claims across 87 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 66 out of 100 for Dr. Altamimi for performance year 2024, reported individually. Dr. Altamimi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Altamimi as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 2,232 general payments to Dr. Altamimi from 85 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. Sanofi and Genzyme US Companies paid the most, $5,425.

Dr. Altamimi graduated from St. George's University School of Medicine in 2004.

Dr. Altamimi is in network with 19 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.